Ftse Mib
34.265,81
-0,32%
DAX
18.499,57
-0,54%
S&P 500
5.631,22
0,28%
NASDAQ
18.472,57
0,40%
Bitcoin
63.171,00
-2,59%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX BioPharmX Corporation (BPMX) BioPharmX Corporation (BPMX) Notizie

BPMX

BioPharmX (BPMX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:BPMX
DataOraFonteTitoloSimboloCompagnia
09/08/201812:15PR Newswire (US)BioPharmX Announces Patent Award, Expanding Protection for Innovations in Solid Dosage FormsAMEX:BPMXBioPharmX Corporation
31/07/201815:15PR Newswire (US)BioPharmX Receives IRB Approval to Initiate Phase 2 Trial of BPX-04 for the Treatment of RosaceaAMEX:BPMXBioPharmX Corporation
19/07/201815:15PR Newswire (US)BioPharmX Announces FDA Grant of CARC Waiver and Post-Hoc Analysis for BPX-01AMEX:BPMXBioPharmX Corporation
06/07/201814:03Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)AMEX:BPMXBioPharmX Corporation
26/06/201822:08Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)AMEX:BPMXBioPharmX Corporation
19/06/201815:15PR Newswire (US)New Patient-Centered Panel Helps BioPharmX Define its Role in the Future of DermatologyAMEX:BPMXBioPharmX Corporation
08/06/201822:11Edgar (US Regulatory)Quarterly Report (10-q)AMEX:BPMXBioPharmX Corporation
07/06/201823:10Edgar (US Regulatory)Current Report Filing (8-k)AMEX:BPMXBioPharmX Corporation
07/06/201822:15PR Newswire (US)BioPharmX Reports First Quarter 2019 Financial ResultsAMEX:BPMXBioPharmX Corporation
24/05/201815:00PR Newswire (US)BioPharmX Studies Show Hydrophilic Topical Minocycline Gels May Be the Preferred Treatment Option for Acne, Rosacea PatientsAMEX:BPMXBioPharmX Corporation
26/04/201823:57Edgar (US Regulatory)Annual Report (10-k)AMEX:BPMXBioPharmX Corporation
26/04/201822:15PR Newswire (US)BioPharmX Reports Fourth Quarter and Full Year 2018 Financial ResultsAMEX:BPMXBioPharmX Corporation
21/03/201801:30PR Newswire (US)BioPharmX Cancels Presentation at Oppenheimer's 28th Annual Healthcare Conference Due to Severe WeatherAMEX:BPMXBioPharmX Corporation
20/03/201814:15PR Newswire (US)U.S. Patent and Trademark Office Awards BioPharmX Patent Protection for Novel Tetracycline-class Topical Drug CompositionsAMEX:BPMXBioPharmX Corporation
14/03/201814:15PR Newswire (US)BioPharmX to Present at Oppenheimer's 28th Annual Healthcare ConferenceAMEX:BPMXBioPharmX Corporation
09/03/201822:03Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:BPMXBioPharmX Corporation
05/03/201815:15PR Newswire (US)BioPharmX to Present at 30th Annual ROTH ConferenceAMEX:BPMXBioPharmX Corporation
14/02/201816:45Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)AMEX:BPMXBioPharmX Corporation
26/01/201815:15PR Newswire (US)BioPharmX To Present Data On New Fluorescence Lifetime Imaging Microscopy to Measure How Effectively Topically Applied Minocy...AMEX:BPMXBioPharmX Corporation
25/01/201814:05InvestorsHub NewsWireTraders News Source Issues Stocks on Watch and a New Feature ReportAMEX:BPMXBioPharmX Corporation
12/01/201815:15PR Newswire (US)BioPharmX To Present BPX-04 Rosacea Data At Two Leading Clinical Conferences This MonthAMEX:BPMXBioPharmX Corporation
07/12/201722:15PR Newswire (US)BioPharmX Reports Third Quarter 2018 Financial ResultsAMEX:BPMXBioPharmX Corporation
04/12/201715:15PR Newswire (US)BioPharmX Demonstrates Topical Minocycline Gel May Exhibit Relevant Antimicrobial and Anti-inflammatory Properties for the Tr...AMEX:BPMXBioPharmX Corporation
30/11/201723:33Edgar (US Regulatory)Statement of Ownership (sc 13g)AMEX:BPMXBioPharmX Corporation
22/11/201712:09Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)AMEX:BPMXBioPharmX Corporation
21/11/201715:05PR Newswire (US)BioPharmX Corporation Announces Pricing of Public OfferingAMEX:BPMXBioPharmX Corporation
21/11/201712:01Edgar (US Regulatory)Notice of Effectiveness (effect)AMEX:BPMXBioPharmX Corporation
20/11/201723:07Edgar (US Regulatory)Securities Registration Statement (s-1/a)AMEX:BPMXBioPharmX Corporation
08/11/201715:15PR Newswire (US)BioPharmX Receives Concurrence from FDA on Phase 3 Acne Study PlansAMEX:BPMXBioPharmX Corporation
23/10/201722:25Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)AMEX:BPMXBioPharmX Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:BPMX

La tua Cronologia

NASDAQ
KTTAW
Pasithea Therapeutics
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network